Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
A Phase II Study With Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Sponsor: Millennium Pharmaceuticals, Inc.
This PHASE2 trial investigates Metastatic Breast Cancer and is currently completed. Millennium Pharmaceuticals, Inc. leads this study, which shows 12 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2021 — Jul 2022 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2019 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2019 — Oct 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jun 2019 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Millennium Pharmaceuticals, Inc.
- SCRI Development Innovations, LLC
For direct contact, visit the study record on ClinicalTrials.gov .